Left, Right & Centre

Talks held between India and China were constructive and cordial, say sources. There was mutual consensus to disengage and all friction areas were discussed. The big question is: Can India trust China after 20 soldiers laid down their lives for the country in Ladakh's Galwan Valley?

The Chinese Army admits that its commanding officer was killed during the Galwan clash on June 15, according to sources. The confirmation came as senior military-level talks between India, China take place on Monday.

As Delhi overtook Tamil Nadu to become the second worst-hit state after Maharashtra, Delhi Chief Minister Arvind Kejriwal on Monday said that the testing in the capital has increased three times and that most cases are mild and in home isolation. He announced more support for such patients like giving oximeters.

At a time when coronavirus cases in India are spiraling like never before, putting a tremendous pressure on the healthcare system, Glenmark Pharmaceuticals has received a nod from the Drugs Controller General of India to manufacture and market antiviral drug Favipiravir, under the brand name Fabiflu. Experts, however, say, like many other new anti-viral drugs, more data, testing and evidence is needed to prove their efficacy.

On Left, Right and Centre, an exclusive report with satellite images on how in 7 days China moved 204 vehicles in the Galwan area just short of the Line of Actual Control. Also, the Prime Minister's Office issues clarification on Prime Minister Narendra Modi's remarks made at an all-party meeting. On the show, we ask: Is there lack of clarity on the Chinese incursion?

At his fourth video conference meeting with chief ministers, sources say Prime Minister Narendra Modi pitched for an extension of the lockdown in red zones that have a high number of cases, while allowing economic activities to carefully resume in orange and green zones with social distancing in place. On Left, Right and Centre, we ask if India can afford another lockdown.

A vaccine for coronavirus may be available in the market as early as the end of September, the chief of the world's largest vaccine maker has told NDTV. The cost, he said, would be roughly around Rs 1,000. We have made a jump start on the manufacturing by the end of May and if the trials that end by September or October are a success. then we will have a product that we can give to India and the world, Adar Poonawalla, the chief of Serum Institute of India, told NDTV today.

he Reserve Bank of India (RBI) on Monday announced a special liquidity facility worth Rs 50,000 crore for mutual funds in a bid to ease liquidity pressures in the sector as well as lift investors' confidence, days after the US-based Franklin Templeton wound up six of its India funds. We are trying to make customers feel more confident. The RBI statement came at a right time because it is now when consumers needed a confidence boost, said Nimesh Shah, MD And CEO, ICICI Prudential Mutual Fund.

No matter how many lockdwon measures are lifted, we are not returning to life as it was before the lockdown, says AIIMS Director Randeep Guleria. There will be a new normal where social distancing will have to be strictly maintained.

The race to develop an effective vaccine against coronavirus has gathered some pace. Clinical trials on humans have begun in the UK with Germany to follow in a few days. On the show we discuss if will we get a vaccine to fight coronavirus sooner than later?